Commentary
Normal antibody response after COVID-19 during treatment with cladribine

https://doi.org/10.1016/j.msard.2020.102476Get rights and content

Highlights

  • Cladribine is a highly effective, recently available treatment in multiple sclerosis.

  • This case report describes a patient with a mild COVID-19 infection during second year treatment with cladribine.

  • Normal immune response with detectable antibodies to SARS-CoV2 three months after the infection.

Abstract

Cladribine is a highly effective, recently available treatment in multiple sclerosis. This case report describes a patient with COVID-19 infection during second year treatment with cladribine. The infection was mild and she was able to mount an adequate immune response with detectable antibodies three months later.

Keywords

Multiple sclerosis
Cladribine
COVID-19
SARS-CoV-2

Cited by (0)

View Abstract